Experts outline safety strategies for radiopharmaceutical treatment of advanced prostate cancer

Dr. Johann De Bono and Dr. Pedro Barata presented a discussion focused on practical methods for monitoring and managing toxicities that arise from radiopharmaceutical therapies used in metastatic castration-resistant prostate cancer.

They highlighted key safety considerations, including baseline assessments, regular laboratory testing, and symptom tracking to detect adverse effects early. The conversation also covered supportive care measures such as hydration, bone health protection, and interventions for hematologic or renal issues.

The session was part of a broader series on radiopharmaceutical approaches in mCRPC, aiming to help clinicians select patients, sequence treatments, and combine modalities safely. Viewers were encouraged to apply these guidelines to improve patient outcomes while minimizing treatment-related risks.